New drug tested to keep aggressive cervical cancer at bay
NCT ID NCT06943833
Summary
This study is testing whether an immunotherapy drug called volrustomig can help prevent cancer from returning in women with high-risk cervical cancer. Participants are women whose cancer hasn't progressed after completing standard chemotherapy and radiation treatment. The goal is to see if adding this drug helps keep the cancer under control longer and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Arkhangelsk, 163045, Russia
-
Research Site
Krasnoyarsk, 660133, Russia
-
Research Site
Moscow, 111123, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 115533, Russia
-
Research Site
Moscow, 117997, Russia
-
Research Site
Moscow, 125284, Russia
-
Research Site
Moscow, 125367, Russia
-
Research Site
Saint Petersburg, 194291, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Ufa, 450054, Russia
-
Research Site
Yekaterinburg, 620036, Russia
Conditions
Explore the condition pages connected to this study.